| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 16.95 mm | 16.95 mm | 16.95 mm | 16.95 mm | 16.95 mm | 16.95 mm |
| Cash burn (monthly) | 4.89 mm | 3.53 mm | 4.67 mm | 5.84 mm | 5.00 mm | 4.82 mm |
| Cash used (since last report) | 20.84 mm | 15.05 mm | 19.88 mm | 24.89 mm | 21.30 mm | 20.53 mm |
| Cash remaining | -3.89 mm | 1.89 mm | -2.94 mm | -7.94 mm | -4.36 mm | -3.59 mm |
| Runway (months of cash) | -0.8 | 0.5 | -0.6 | -1.4 | -0.9 | -0.7 |
| 13F holders | Current |
|---|---|
| Total holders | 78 |
| Opened positions | 10 |
| Closed positions | 9 |
| Increased positions | 31 |
| Reduced positions | 16 |
| 13F shares | Current |
|---|---|
| Total value | 42.26 bn |
| Total shares | 57.51 mm |
| Total puts | 500.00 |
| Total calls | 37.40 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| TAK Takeda Pharmaceutical Company Limited | 8.78 mm | $19.23 mm |
| EcoR1 Capital Fund | 6.08 mm | $24.45 mm |
| Rubric Capital Management | 5.32 mm | $6.27 bn |
| BlackRock | 4.31 mm | $5.09 bn |
| Madison Avenue Partners | 4.12 mm | $4.86 bn |
| Biotechnology Value Fund L P | 3.85 mm | $4.43 mm |
| BVF | 3.85 mm | $4.55 bn |
| Vanguard | 3.14 mm | $3.71 bn |
| Siren, L.L.C. | 2.85 mm | $3.36 bn |
| Acadian Asset Management | 1.85 mm | $2.18 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 27 Jan 25 | Margaret A. Alexander | Common Stock | Buy | Acquire P | No | No | 0.73 | 6,810 | 4.97 k | 34,935 |
| 12 Dec 24 | Kevin Joseph Fitzgerald | Stock Option Common Stock | Grant | Acquire A | No | No | 1.06 | 90,000 | 95.40 k | 90,000 |
| 12 Dec 24 | Duncan Barbara Gayle | Stock Option Common Stock | Grant | Acquire A | No | No | 1.06 | 90,000 | 95.40 k | 90,000 |
| 12 Dec 24 | Bernstein Karen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.06 | 90,000 | 95.40 k | 90,000 |
| 12 Dec 24 | Friedman Bart | Stock Option Common Stock | Grant | Acquire A | No | No | 1.06 | 90,000 | 95.40 k | 90,000 |
